A best evidence topic in thoracic surgery was written according to a structured protocol. The question addressed was whether it is valuable and safe to perform reoperation for recurrent thymoma. Altogether, more than 500 papers were found using the reported search, of which 15 represented the best evidence to answer the clinical question. The authors, journal, date and country of publication, patient group studied, study type, relevant outcomes and results of these papers are tabulated. This paper includes 1 level 1a study and 15 level 2b studies. The operative mortality was reported in six studies, ranging from 0 to 13.3%, and the operative morbidity in five studies, ranging from 0 to 32.1%. Most patients suffering from operative mortality (5/5) and morbidity (16/19) had myasthenia gravis. One meta-analysis demonstrated improved rates of long-term overall survival in patients with recurrent thymoma who were treated surgically compared with those treated non-surgically. Ten studies showed better survival after surgical treatment than after non-surgical treatment with the difference being statistically significant in 4 of them. Two studies reported that the prognosis in patients with complete reresection was comparable with that of patients without recurrence. One study found that patients with a thymus-related syndrome improved after re-resection. Another two studies revealed that debulking surgery for recurrent thymoma was associated with poorer survival and worse outcomes than both complete resection and non-surgical therapy. From the papers identified in our search, we can conclude that reoperation can be performed with acceptable morbidity and low mortality in appropriately selected patients with locally and/or regionally recurrent thymoma. Both survival and thymus-related syndromes are improved if the recurrence is surgically resected when compared with other medical treatments. Debulking surgery should be limited to those few selected patients in whom other treatment options are not available. In addition, morbidity and mortality most commonly occur in association with myasthenia gravis, and hence medical control of this should be optimized prior to reoperation.
INTRODUCTION
A best evidence topic was constructed according to a structured protocol. This is fully described in the ICVTS [1] .
THREE-PART QUESTION
In patients who [ 
CLINICAL SCENARIO
A 49-year old woman underwent a complete thymectomy for thymoma via a unilateral video-assisted thoracoscopic surgery approach 3 years ago and her postoperative course had been uneventful. Now, she presents with a new well-circumscribed 1.5-cm nodule which was incidentally found on the follow-up CT scan. It is located on the right costal pleura, and is suspected to be a pleural recurrence of the thymoma. Her therapeutic options include surgical resection, radiotherapy and/or chemotherapy. On discussion with the patient, she expresses concerns regarding whether surgical resection is a safe option and whether it is superior to other treatments. You resolve to check the literature yourself. The complete reresection group had better survival after recurrence than the [6] were from the same institution, and therefore, the latter two studies were excluded to avoid duplication. This left a final selection of 15 papers which are presented in Table 1 .
SEARCH STRATEGY

Continued
RESULTS
No randomized trial evidence was found, and all studies were retrospective case series, except for one meta-analysis. The operative mortality rate was reported in 6 studies, ranging from 0 to 13.3%, and the operative morbidity rate in 5 studies, ranging from 0 to 32.1%. Sandri et al. [7] compared patients receiving surgery versus those receiving chemo/radiotherapy for recurrence, and found no difference between the groups in terms of rates of overall survival (OS) after initial thymectomy and disease-free survival after treatment for recurrence (P = 0.19 and P = 0.23, respectively). However, in patients with intrathoracic recurrence, a trend was observed for better survival in patients treated with surgery compared with patients treated with radio and/or chemotherapy alone, although the difference fell short of statistical significance (P = 0.12).
Hamaji et al. [8] reviewed the literature available before the year 2013 and developed evidence-based recommendations. The authors demonstrated improved long-term survival in patients who were treated surgically compared with those treated non-surgically, including 5-and 10-year OS after initial thymectomy (risk ratio: 0.34 and 0.47) and 5-year OS after recurrence (risk ratio: 0.44).
In 2012 Bae et al. [11] reported that there was no postoperative 30-day mortality after reresection but 3 cases of minor morbidity, including 1 of chylothorax and 2 of prolonged chest drainage for more than 7 days. Regarding survival after initial resection, they found that in patients with complete reresection, their survival was comparable with that of patients without recurrence (P = 0.618). The same result was also found by Blumberg et al. [19] .
Margaritora et al. [12] , in a retrospective review of their 40-year experience, reported 5-, 10-and 15-year OS rates of 64, 51 and 43%, respectively, for patients with recurrence. In surgically managed patients, the postoperative mortality was nil, whereas postoperative complications occurred in 8 patients (27%), 7 of whom had myasthenia gravis (MG). The 5-year survival was significantly better when reoperation was performed for recurrence (91%, P = 0.001).
Marulli et al. [2] reviewed the survival outcomes of 43 patients treated at four different Italian institutions for recurrent thymoma. Surgical treatment of recurrence led to a significantly better 10-year survival rate from the first intervention in comparison with medical treatments alone (75 vs 13%, P < 0.0001).
Lucchi et al. [14] targeted patients with pleural thymoma recurrences and 15 of 20 patients had a thymus-related syndrome. After a median follow-up of 98 months after reresection, the majority of patients who had a thymus-related syndrome experienced symptomatic improvement and only 1 patient worsened. The authors reported no mortality and an acceptable percentage of morbidity (n = 3, 13.6%). Similarly, Evoli et al. [16] studied recurrent thymoma in patients with MG and their results proved that reoperation appeared effective in prolonging survival (87.5 vs 25%, P-value not provided).
Haniuda et al. [17] reported that of the 15 patients receiving reoperation, 2 died during the postoperative course. Both patients had developed severe MG paralleling the recurrence of thymoma, and 1 patient died of bleeding and the other of respiratory failure due to pneumonia. The authors reported no operative morbidity. On survival analysis, reoperation was found to have no beneficial effect on post-recurrence survival (P = 0.08).
Regnard et al. [18] investigated patients undergoing reoperation for recurrent thymoma and found that 3 (11%) patients died during the postoperative course. All 3 had MG. The overall morbidity rate was 33%, but the morbidity rate among myasthenic patients was 60%. Survival seemed better after complete resection than after incomplete resection, but the difference fell just short of statistical significance (P = 0.08). Two studies addressed the effectiveness of debulking surgery in recurrent thymoma. Margaritora et al. [12] revealed a worse long-term survival in patients who underwent debulking surgery than in those who received medical treatment (25 vs 35%). Ruffini et al. [4] showed that 5-and 10-year OS rates were better in patients receiving radiotherapy alone than in those receiving debulking surgery, although the absolute differences were not reported.
CLINICAL BOTTOM LINE
Although recurrent thymoma after initial thymectomy is rare, the evidence suggests that reoperation can be performed with acceptable morbidity and low mortality in appropriately selected patients with locally and/or regionally recurrent thymoma. Both survival and thymus-related syndromes are improved if the recurrence is surgically resected when compared with other medical treatments. Debulking surgery should be limited to those few selected patients where other treatment options (such as radiotherapy) are not available. In addition, most instances of morbidity and mortality during reoperation occur in association with MG, and hence medical control of this should be optimized prior to reoperation.
